Generation Bio Co
NASDAQ:GBIO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.12
4.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Generation Bio Co
Generation Bio Co
Operating Income
Generation Bio Co
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Generation Bio Co
NASDAQ:GBIO
|
Operating Income
-$138.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$15.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$10.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$6.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Generation Bio Co
Glance View
Generation Bio Co. is a genetic medicine company focused on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2020-06-12. The firm through its non-viral genetic medicine platform, is engaged in developing genetic medicines to provide genetic payloads, which include large and multiple genes to a range of cell types across a range of diseases. The company is comprised of three component technologies: ceDNA, ctLNP and ceDNA manufacturing process. ceDNA is an engineered, double-stranded, linear, covalently closed-ended deoxyribonucleic acid (DNA) construct, which includes the gene of interest and associated regulatory sequences. The company has produced ceDNA constructs of approximately eight kilobases. Its ctLNP delivery system builds upon clinically validated lipid nanoparticles and is designed to allow for repeat dosing of a genetic payload without stimulating an immune response, such as antibody production. Its ceDNA manufacturing process uses its own cell-free rapid enzymatic synthesis (RES) to produce ceDNA.
See Also
What is Generation Bio Co's Operating Income?
Operating Income
-138.6m
USD
Based on the financial report for Dec 31, 2023, Generation Bio Co's Operating Income amounts to -138.6m USD.
What is Generation Bio Co's Operating Income growth rate?
Operating Income CAGR 5Y
-30%
Over the last year, the Operating Income growth was -2%. The average annual Operating Income growth rates for Generation Bio Co have been -20% over the past three years , -30% over the past five years .
You don't have any saved screeners yet
